Skip to content
OpenCapital
Get started

CRISPR Therapeutics CRSP Cash & Equivalents

Cash & Equivalents at other companies

Beam Therapeutics logo
Beam TherapeuticsBEAM
$288.29M-45.4%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$241.21M+91.4%
Celcuity logo
CelcuityCELC
$145.19M+781%
Arrowhead Research logo
Arrowhead ResearchARWR
$188.52M+1.5%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$501.31M+62.4%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$97.19M+100%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.33B+56.4%

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CRISPR Therapeutics's cash & equivalents?
CRISPR Therapeutics (CRSP) reported cash & equivalents of $423.31M in Q1 2026.
How has CRISPR Therapeutics's cash & equivalents changed year-over-year?
CRISPR Therapeutics's cash & equivalents increased by 80.0% year-over-year, from $235.18M to $423.31M.
What is the long-term trend for CRISPR Therapeutics's cash & equivalents?
Over 5 years (2020 to 2025), CRISPR Therapeutics's cash & equivalents has grown at a -21.5% compound annual growth rate (CAGR), from $1.17B to $347.56M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.